Article

Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation.

Department of Medicine, Ohio State University College of Medicine, Columbus 43210, USA.
Circulation Research (Impact Factor: 11.86). 10/2006; 99(5):477-84. DOI: 10.1161/01.RES.0000238376.72592.a2
Source: PubMed

ABSTRACT Women are at high risk of dying from unrecognized cardiovascular disease. Many differences in cardiovascular disease between men and women appear to be mediated by vascular smooth muscle cells (SMC). Because estrogen reduces the proliferation of SMC, we hypothesized that activation of estrogen receptor-alpha (ERalpha) by agonists or by growth factors altered SMC function. To determine the effect of growth factors, estrogen, and ERalpha expression on SMC differentiation, human aortic SMC were cultured in serum-free conditions for 10 days. SMC from men had lower spontaneous expression of ERalpha and higher levels of the differentiation markers calponin and smooth muscle alpha-actin than SMC from women. When SMC containing low expression of ERalpha were transduced with a lentivirus containing ERalpha, activation of the receptor by ligands or growth factors reduced differentiation markers. Conversely, inhibiting ERalpha expression by small interfering RNA (siRNA) in cells expressing high levels of ERalpha enhanced the expression of differentiation markers. ERalpha expression and activation reduced the phosphorylation of Smad2, a signaling molecule important in differentiation of SMC and initiated cell death through cleavage of caspase-3. We conclude that ERalpha activation switched SMC to a dedifferentiated phenotype and may contribute to plaque instability.

0 Bookmarks
 · 
131 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Arterial elastic properties and wave reflections constitute left ventricular pulsatile afterload and are directly related to cardiovascular morbidity and mortality. During the aging process, elastic arteries stiffen and increase pulse wave velocity, causing the reflected pressure wave to arrive at the heart during systole, and augment systolic and pulse blood pressure, resulting in left ventricular hypertrophy. The incidence of cardiovascular disease is much greater in men aged 30-50 years compared with women of a similar age. Among women, the incidence of cardiovascular disease increases dramatically after menopause, which occurs at an average age of 52 years. This observation has lead to the belief that sex hormones produced premenopausally impede or delay the progression of cardiovascular disease. Therefore, it appears logical that the administration of female sex hormones, hormone treatment (HT), estrogen alone or with progesterone should provide some degree of cardiovascular protection. This idea was supported by experiments in animals and isolated arterial segments demonstrating that HT increases plasma nitric oxide, decreases endothelin-1 levels and causes smooth muscle relaxation. Also, 17β-estradiol administration decreases collagen and increases elastin in the aortic wall of rats. These experimental studies suggest an improvement in both elastic and muscular artery properties and favorabe modifications of arterial wave reflection characteristics. Furthermore, HT improves lipoprotein metabolism and reduces coronary artery plaque formation in animal models. Unfortunately, observational and interventional studies in postmenopausal women that have evaluated the impact of HT on cardiovascular changes have produced inconsistent and inconclusive results. Most studies agree that arterial stiffness increases after menopause, partly due to advancing age and reduced estrogen production. Results from most studies that were designed to investigate the effects of HT on arterial properties have shown a selective decrease in elastic artery stiffness with little effect on muscular arteries. This beneficial effect was observed only if estrogen alone was administered. The main objective of this review is to discuss the ill effects of arterial stiffness in general and attempt to translate information from previous experimental studies to those in postmenopausal women and explain the beneficial effects of HT on arterial stiffness and improvement in left ventricular afterload.
    Expert Review of Endocrinology &amp Metabolism 08/2007; 2(5):653-665.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sex steroid hormones differently control the major physiological processes in male and female organisms. In particular, their effects on vascular smooth muscle cells (VSMCs) migration are at the root of sex/gender-related differences reported in the cardiovascular system. Several exogenous substances, defined endocrine disruptor chemicals (EDCs), could interfere with these androgen and estrogen effects; however, the sex/gender-related susceptibility of VSMC motility to EDCs is completely unknown. Here, the effect of naturally occurring (naringenin, Nar) and synthetic (bisphenol A, BPA) EDCs on male and female VSMC motility has been evaluated. 17β-estradiol (E2, 0.1 nM to 1 µM) induced a dose-dependent inhibition of motility in female-derived VSMC. In contrast, neither dihydrotestosterone (DHT, 0.01 to 100 nM) nor the common precursor of sex steroid hormones, testosterone (Tes, 0.01 to 100 nM) modified male-derived VSMC motility. Estrogen receptor (ER) β subtype-dependent activation of p38 was necessary for the E2 effect on cell motility. High BPA concentration prevented E2 effects in female-derived cells being without any effect in male-derived cells. Nar mimicked E2 effects on female-derived cells even in the presence of E2 or BPA. Intriguingly, Nar also inhibited the male-derived VSMC mobility. This latter effect was prevented by ERβ inhibitor, but not by the androgen receptor (AR) inhibitor. As a whole, ERβ-dependent signals in VSMC results more susceptible to the impact of EDCs than AR signals suggesting a possible high and overall susceptibility of female to EDCs. However, several male-derived cells, including VSMC, express ERβ which could also serve as target of EDC disruption in male organisms. J. Cell. Physiol. © 2013 Wiley Periodicals, Inc.
    Journal of Cellular Physiology 12/2013; · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The anti-inflammatory and neuro-protective effects of estrogen on multiple sclerosis (MS) have been reported in previous studies. Evidence has been found that estrogen can inhibit axonal loss in the MOG-induced experimental autoimmune encephalomyelitis (EAE) model of MS. Rho-kinase (ROCK) mediates axonal growth-inhibitory signals via the Rho/ Rho-kinase pathway. The inhibition of ROCK decreases axonal loss in EAE. However, there is no study reporting the association between estrogen and ROCK in MS and EAE. We examined the anti-inflammatory and axonal protective effects of estrogen and explored the probable mechanism whereby estrogen inhibits ROCK through ERα in EAE rats. Results show that 17β-estradiol (E2) can significantly avoid the loss of neurological function in EAE rats. E2 also decreased the infiltration of inflammatory cells and cytokines including IL-1β, TNF-α and IL-17, but increased the expression of IL-4. E2 inhibited the expression of ROCK and NF-200 in EAE rats. The inhibitory effect on ROCK was abolished when non-selective estrogen receptor(ER) antagonist ICI 182780 was added to E2. Furthermore, the expression of ROCK was inhibited by ERα-selective ligand agonist propyl pyrazole triol (PPT). ERβ-selective ligand WAY-202041 has no effect on the expression of ROCK. These observations suggest that estrogen inhibits the expression of ROCK in EAE rats, and that the inhibitory effects are mediated by ERα rather than ERβ.
    Synapse 02/2013; · 2.31 Impact Factor

Full-text

Download
32 Downloads
Available from
Jun 2, 2014